Ashfield Capital Partners’s 9 Meters Biopharma NMTR Stock Holding History

Ashfield Capital Partners’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7K	Hold	1,668	–	–	﹤0.01%	228
2022 Q2	$9K	Hold	1,668	–	–	﹤0.01%	229
2022 Q1	$20K	Hold	1,668	–	–	﹤0.01%	235
2021 Q4	$33K	Hold	1,668	–	–	﹤0.01%	235
2021 Q3	$43K	Hold	1,668	–	–	﹤0.01%	231
2021 Q2	$37K	Hold	1,668	–	–	﹤0.01%	232
2021 Q1	$39K	Hold	1,668	–	–	﹤0.01%	231
2020 Q4	$29K	Hold	1,668	–	–	﹤0.01%	233
2020 Q3	$27K	Hold	1,668	–	–	﹤0.01%	220
2020 Q2	$19K	Hold	1,668	–	–	﹤0.01%	215
2020 Q1	$17K	Buy	+1,668	New	+$20.9K	﹤0.01%	214

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Ashfield Capital Partners's NMTR Position: Q3 2022 in Review

Ashfield Capital Partners held its 9 Meters Biopharma (NMTR) position steady in Q3 2022 at 1,668 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #228.

Ashfield Capital Partners first reported a position in NMTR in Q1 2020 and has held it in 11 quarters since. The position peaked at $43K in Q3 2021. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

Ashfield Capital Partners held 1,668 shares of 9 Meters Biopharma worth $7K as of Q3 2022.
Ashfield Capital Partners left its 9 Meters Biopharma share count unchanged in Q3 2022.
9 Meters Biopharma made up ﹤0.01% of Ashfield Capital Partners's portfolio in Q3 2022, its #228 holding.
Ashfield Capital Partners first reported a position in 9 Meters Biopharma in Q1 2020 and has held it in 11 quarters since.
Ashfield Capital Partners's 9 Meters Biopharma position peaked at $43K in Q3 2021.
74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.